about
Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational studyOptimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae.Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated CandidiasisDetermination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection modelNeutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseasesApplication of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.Etiologic diagnosis of chronic osteomyelitis: a prospective study.An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacinGeneric vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection modelA strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic miceImpact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.Dependence to legally prescribed opioid analgesics in a university hospital in Medellin-Colombia: an observational study.Antifungal pharmacodynamics: Latin America's perspective.In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.Perspectives for the structure-based design of acetylcholinesterase reactivators.Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia.CIEMTO: the new drug and poison research and information center in Medellín, Colombia.Uso del Registro de Solicitudes de Medicamentos no Incluidos en el Listado de Medicamentos Esenciales como Nueva Fuente de Información en los Sistemas Nacionales de Farmacovigilancia.Myoclonus induced by salbutamol: A case reportNontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatinBurden of paraquat poisoning in the department of Antioquia, Colombia[Physicians´ insight about adverse drug reaction to frequently used medication groups in Bogotá (Colombia)]About the validation of animal models to study the pharmacodynamics of generic antimicrobialsComparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damageToxicity induced by multiple high doses of vitamin B12 during pernicious anemia treatment: a case reportNonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With TuberculosisThe road to biosimilars in rare diseases - ongoing lessons from Gaucher disease[Effectiveness of the antibiotic combinations for enterococcal infections treatment: a critical review]A counterfeit multivitamin product inducing severe bleeding disorders in humansPrediction of Ligands Binding Acetylcholinesterase with Potential Antidotal Activity: A Virtual Screening Approach
P50
Q24794147-7FBE0314-B3F7-4EE4-9C9A-0BB1B15DAA8EQ24816151-2B73D85A-F12B-4B96-ADBD-B7E2267C72FDQ27347943-1BA3D4D3-033D-403D-BF79-F97EDDEC992AQ28474000-0AA12427-9292-42A7-9607-D8BBD6F202B7Q33236887-07494674-659B-4658-8228-9EFC4A1CB44AQ33400567-C0A13996-32F5-45E8-AA8F-017A31405067Q33595346-79586471-18E0-4BE4-982F-FEFE129A767AQ34482775-C60FBE96-944F-449C-9D18-072535B782F8Q34922257-B7185428-C813-424D-A2BC-78E09CF3E6DFQ34922857-9527C6AF-C2DA-4C20-99D6-5AD5509FA187Q35666429-1AAAEA79-6FD3-4B20-BA9A-8A7BB1BF9351Q35761235-EA9B3C6F-6D16-4378-97B4-2A7D19AB3CD5Q36020757-5C80889B-B06E-48EC-8782-23F36FE46BB6Q36131630-363C41A6-6E79-4AD7-9FB5-276854E70ABEQ36131787-E84ECDF2-5DA3-4C5E-98F8-27917A0F4E1EQ39002088-FBA9DC97-5A13-40B3-931B-40237811027EQ39092509-A619564A-21E4-4733-A6FD-EA22BF7B0324Q39567158-D31A4660-851F-402F-8883-60794E4D974FQ41613745-AD2AC0FF-1A0E-4E8C-94E3-D1BEAFFAA2CAQ43288031-621BBD76-B17C-411C-8A28-BA432D23E48EQ48280264-6AD898AC-55D1-4AAF-9ABE-B71A87CA2980Q54515941-409E4C78-6266-45A2-94D4-7EF3A55EC610Q58557113-A6C3A50A-AF0E-434A-BDEC-0EE0BDBFCC04Q64232445-19D7BA5D-82C7-474D-B673-795A0C294081Q64245929-4B210F76-2284-47D3-B5DB-FE9761CDB795Q86277038-3B51FC43-94C9-42B9-8F43-1F4729EC6452Q87788929-B79A897B-690C-453C-9884-5B6609953451Q90166477-AD6C4108-E361-49D2-8569-3959E3F62438Q90279986-6CD0F8C4-E3A7-41B6-8C67-125B66E7E593Q91279713-54B0533D-2D65-4B1E-AA86-AC2DED6F0AFBQ91801763-AFE208AA-F332-43DC-A5B2-8149110CFB27Q92145679-CB7A1A42-027D-491A-98C4-05E4FEC91F63Q92547161-D9F9419A-7D97-43AB-AF16-579B63DCA706Q92869093-4EDDC09F-26CF-43B6-9A53-2E52A7BBDA21
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andres F. Zuluaga
@ast
Andres F. Zuluaga
@en
Andres F. Zuluaga
@es
Andres F. Zuluaga
@nl
type
label
Andres F. Zuluaga
@ast
Andres F. Zuluaga
@en
Andres F. Zuluaga
@es
Andres F. Zuluaga
@nl
prefLabel
Andres F. Zuluaga
@ast
Andres F. Zuluaga
@en
Andres F. Zuluaga
@es
Andres F. Zuluaga
@nl
P1053
K-7366-2016
P106
P1153
35422992800
P21
P31
P3829
P496
0000-0001-5656-4153